Since the start of the COVID-19 pandemic there have been remarkable research and innovation efforts to fight the SARS-COV-2 virus….Read More
Why the EPO’s Enlarged Board of Appeal’s decision in G2/21 will impact inventions relating to life sciences and chemistry
The European Patent Office’s (EPO) Enlarged Board of Appeal’s decision in G2/21 primarily relates to when data that only becomes…Read More
Data versus time in clinical trials: attaining the perfect balance
Clinical trials are an expensive and risky business. The investment of time, resources and costs grows with progression through the…Read More
Plausibility at the EPO – how much data or experimental information is enough?
A patent for an invention provides its owner with the right to exclude others from making, using, offering for sale…Read More